Why Sequenom, Inc. Shares Could Soar 25%
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense.
What: Shares of Sequenom gained about 2% today after Jefferies resumed coverage on the genetic analysis specialist with a buy rating.
So what: Along with the upgrade, analyst Brandon Couillard boosted his price target to $5.00 (from $4.50), representing about 26% worth of upside to yesterday's close. So while contrarian traders might be turned off by Sequenom's year-to-date price strength, Couillard's call could reflect a sense on Wall Street that its growth prospects still aren't fully baked into the valuation.
Now what: Jefferies lifted its 2014 EPS outlook for Sequenom from ($0.75) to ($0.31). "Our revised revenue and EPS forecasts reflect the effects of SQNM's recent divestiture of its Biosciences unit, as well as expectations for a profitability & cash flow inflection in 4Q14," said Couillard. Given Jefferies' solid stock-picking track record -- currently ranked in the top 15% of our CAPS community -- biotech-savvy Fools might want to take a closer look at Sequenom.
Warren Buffett: This new technology is a "real threat"
At the recent Berkshire Hathaway annual meeting, Warren Buffett admitted this emerging technology is threatening his biggest cash-cow. While Buffett shakes in his billionaire-boots, only a few investors are embracing this new market which experts say will be worth over $2 trillion. Find out how you can cash in on this technology before the crowd catches on, by jumping onto one company that could get you the biggest piece of the action. Click here to access a FREE investor alert on the company we're calling the "brains behind" the technology.
The article Why Sequenom, Inc. Shares Could Soar 25% originally appeared on Fool.com.Brian Pacampara has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.